US 12,404,257 B2
Advantageous benzofuran compositions for mental disorders or enhancement
Matthew Baggott, Redwood City, CA (US)
Assigned to TACTOGEN INC, Palo Alto, CA (US)
Filed by TACTOGEN INC, Palo Alto, CA (US)
Filed on Feb. 13, 2025, as Appl. No. 19/053,277.
Application 19/053,277 is a continuation of application No. 18/895,095, filed on Sep. 24, 2024.
Application 18/895,095 is a continuation of application No. 18/371,935, filed on Sep. 22, 2023.
Application 18/371,935 is a continuation of application No. 18/077,966, filed on Dec. 8, 2022, granted, now 11,767,305, issued on Sep. 26, 2023.
Application 18/077,966 is a continuation of application No. PCT/US2021/036479, filed on Jun. 8, 2021.
Claims priority of provisional application 63/165,731, filed on Mar. 24, 2021.
Claims priority of provisional application 63/149,223, filed on Feb. 13, 2021.
Claims priority of provisional application 63/062,434, filed on Aug. 6, 2020.
Claims priority of provisional application 63/055,897, filed on Jul. 23, 2020.
Claims priority of provisional application 63/048,616, filed on Jul. 6, 2020.
Claims priority of provisional application 63/046,496, filed on Jun. 30, 2020.
Claims priority of provisional application 63/036,382, filed on Jun. 8, 2020.
Prior Publication US 2025/0188049 A1, Jun. 12, 2025
Int. Cl. C07D 307/81 (2006.01); A61P 25/18 (2006.01); A61P 25/24 (2006.01)
CPC C07D 307/81 (2013.01) [A61P 25/18 (2018.01); A61P 25/24 (2018.01)] 30 Claims
 
1. A method for the treatment of a central nervous system disorder comprising administering an effective amount of an entactogen, and an additional active compound,
wherein the entactogen is selected from 5-MAPB, 6-MAPB, 5-MBPB, 6-MBPB, Bk-5-MAPB, Bk-6-MAPB, Bk-5-MBPB, and Bk-6-MBPB, or a pharmaceutically acceptable salt or mixed salt thereof, and
wherein the additional active compound is an alpha antagonist, a beta antagonist, or a mixed alpha and beta antagonist, or a pharmaceutically acceptable salt or mixed salt thereof.